Matches in Wikidata for { <http://www.wikidata.org/entity/Q90601458> ?p ?o ?g. }
Showing items 1 to 67 of
67
with 100 items per page.
- Q90601458 description "articolo scientifico (pubblicato il 2019)" @default.
- Q90601458 description "artikull shkencor i botuar më 01 shkurt 2019" @default.
- Q90601458 description "artículu científicu espublizáu en febreru de 2019" @default.
- Q90601458 description "im Februar 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q90601458 description "scientific article published on 01 February 2019" @default.
- Q90601458 description "wetenschappelijk artikel" @default.
- Q90601458 description "наукова стаття, опублікована 1 лютого 2019" @default.
- Q90601458 name "Correction to: Inhibitor development, safety, and efficacy of Advate® in previously untreated patients with hemophilia A in a postmarketing surveillance in Japan" @default.
- Q90601458 name "Correction to: Inhibitor development, safety, and efficacy of Advate® in previously untreated patients with hemophilia A in a postmarketing surveillance in Japan" @default.
- Q90601458 name "Correction to: Inhibitor development, safety, and efficacy of Advate® in previously untreated patients with hemophilia A in a postmarketing surveillance in Japan" @default.
- Q90601458 type Item @default.
- Q90601458 label "Correction to: Inhibitor development, safety, and efficacy of Advate® in previously untreated patients with hemophilia A in a postmarketing surveillance in Japan" @default.
- Q90601458 label "Correction to: Inhibitor development, safety, and efficacy of Advate® in previously untreated patients with hemophilia A in a postmarketing surveillance in Japan" @default.
- Q90601458 label "Correction to: Inhibitor development, safety, and efficacy of Advate® in previously untreated patients with hemophilia A in a postmarketing surveillance in Japan" @default.
- Q90601458 prefLabel "Correction to: Inhibitor development, safety, and efficacy of Advate® in previously untreated patients with hemophilia A in a postmarketing surveillance in Japan" @default.
- Q90601458 prefLabel "Correction to: Inhibitor development, safety, and efficacy of Advate® in previously untreated patients with hemophilia A in a postmarketing surveillance in Japan" @default.
- Q90601458 prefLabel "Correction to: Inhibitor development, safety, and efficacy of Advate® in previously untreated patients with hemophilia A in a postmarketing surveillance in Japan" @default.
- Q90601458 P1433 Q90601458-BDE9288F-9FE0-4272-93B4-85A40AFB27BB @default.
- Q90601458 P1476 Q90601458-87310EE2-D5CC-4C7B-A72F-7FC7CDC8E5FA @default.
- Q90601458 P2093 Q90601458-1D16E949-13C5-4500-91F9-033C028CB1E8 @default.
- Q90601458 P2093 Q90601458-21D8B996-F54C-4A7F-A71A-93CFD9835603 @default.
- Q90601458 P2093 Q90601458-4D4A2C4A-5D6C-4418-8D6D-7466212D00B9 @default.
- Q90601458 P2093 Q90601458-5EC771BD-0031-4C86-BE1C-F2FCD4AD55F6 @default.
- Q90601458 P2093 Q90601458-75781200-1617-4BD0-A5D0-085F647CE71D @default.
- Q90601458 P2093 Q90601458-7F740658-E14D-4494-B5FB-A8E99AD2E318 @default.
- Q90601458 P2093 Q90601458-7F7D3074-0C27-44EA-9037-B71FD0FD730A @default.
- Q90601458 P2093 Q90601458-B2E91F03-6FFB-4D71-B6B3-C8BA252FD2C7 @default.
- Q90601458 P2093 Q90601458-C786273B-26C5-4167-B940-B788279F645A @default.
- Q90601458 P2093 Q90601458-D3E6712F-909F-4331-9372-E7DBED77FBAE @default.
- Q90601458 P2093 Q90601458-DF4D71EA-D179-4C6B-8A75-328148FC2C69 @default.
- Q90601458 P304 Q90601458-35BC8540-31CD-4023-92D8-0BE94F65BCA8 @default.
- Q90601458 P31 Q90601458-84BBB7BD-972B-4B9E-B1A6-7117A3A765FE @default.
- Q90601458 P31 Q90601458-AE71FAB9-AA85-48E7-A7C3-9F2D7B712308 @default.
- Q90601458 P356 Q90601458-5298255F-F78C-4491-82ED-FCE1E28A3B9F @default.
- Q90601458 P433 Q90601458-D6963DF2-80D0-46C6-A817-69B8F3B4C89D @default.
- Q90601458 P478 Q90601458-C318E6DD-676D-4E7C-A32C-81FF8784B2C3 @default.
- Q90601458 P50 Q90601458-584DEE9A-0531-4391-8E2F-8AC9B6E3F801 @default.
- Q90601458 P577 Q90601458-7D947453-E760-452A-8F74-5580FAE9091C @default.
- Q90601458 P698 Q90601458-249D9F86-A92E-49CE-96B4-C14B5072C803 @default.
- Q90601458 P921 Q90601458-7074DC88-01BE-4662-BC51-A9601EBD5242 @default.
- Q90601458 P921 Q90601458-794D2024-4A0A-41A3-906D-E3CC76F70B0E @default.
- Q90601458 P356 S12185-018-02564-Z @default.
- Q90601458 P698 30560315 @default.
- Q90601458 P1433 Q6051416 @default.
- Q90601458 P1476 "Correction to: Inhibitor development, safety, and efficacy of Advate® in previously untreated patients with hemophilia A in a postmarketing surveillance in Japan" @default.
- Q90601458 P2093 "Akira Shirahata" @default.
- Q90601458 P2093 "Akira Yoshioka" @default.
- Q90601458 P2093 "Haruhiko Uchikawa" @default.
- Q90601458 P2093 "Hiroshi Takagi" @default.
- Q90601458 P2093 "Junki Takamatsu" @default.
- Q90601458 P2093 "Katsuyuki Fukutake" @default.
- Q90601458 P2093 "Keiji Nogami" @default.
- Q90601458 P2093 "Masashi Taki" @default.
- Q90601458 P2093 "Morio Arai" @default.
- Q90601458 P2093 "Tadashi Matsushita" @default.
- Q90601458 P2093 "Werner Engl" @default.
- Q90601458 P304 "241" @default.
- Q90601458 P31 Q13442814 @default.
- Q90601458 P31 Q1348305 @default.
- Q90601458 P356 "10.1007/S12185-018-02564-Z" @default.
- Q90601458 P433 "2" @default.
- Q90601458 P478 "109" @default.
- Q90601458 P50 Q111804989 @default.
- Q90601458 P577 "2019-02-01T00:00:00Z" @default.
- Q90601458 P698 "30560315" @default.
- Q90601458 P921 Q17 @default.
- Q90601458 P921 Q2092064 @default.